![](/images/2013/post-sep.jpg)
MyFloraDNA Launches Crowdfunding Campaign to Combat Peanut Allergies with CRISPR Technology
MyFloraDNA aims to provide a safer alternative for people who suffer from peanut allergies, while also tackling critical issues in agricultural innovation.
The company is now offering a unique investment opportunity through StartEngine Capital, LLC. MaxGene Bioscience is pioneering the SafePeanut Research Project, targeting the vast peanut and peanut-allergy market valued at $90.4B. Their team utilizes CRISPR technology to create non-allergenic peanuts, offering a revolutionary solution that ensures safer consumption, reduces emergencies, saves on healthcare costs, and opens up new markets.
MyFloraDNA has already raised $890,000 for MaxGene Bioscience to develop CRISPR protocols for crop enhancement. Now, they are ready to revolutionize the peanut industry and help millions of Americans with our non-allergenic peanut innovation.
"Our focus has always been on creating solutions that are not only innovative but also have a profound, positive impact on society," added Ajith Anand, CSO of MyFloraDNA. "The development of the allergy-free peanut is a testament to our vision and expertise, and we are confident it will be a game-changer in the industry. The crowdfunding platform will allow us to engage directly with our supporters and accelerate the delivery of these life-saving innovations."
About MyFloraDNA Group
MyFloraDNA Group is an innovation-driven cluster of companies including MyFloraDNA Lab and MaxGeneBioScience. They pioneer advances in plant genetics and biotechnology, using MyFloraDNA Lab’s cutting-edge research to uncover genetic insights that MaxGeneBioScience transforms into sustainable applications. Together, they improve agricultural productivity and sustainability with solutions from genetic analysis to field-ready products.
Angel Fernandez
MyFloraDNA Group
+1 530-564-2049
email us here
Unlocking Solutions: CRISPR for Peanut Allergies 🥜
![](https://supermarkets.einnews.com/tracking/article.gif?aid=728430807§ion=einpresswire&a=1rDIip-Swkpq3vPj&i=WrkeXb7lKerDOBrx)
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.